New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients

  • Authors:
    • Yukoh Itoh
    • Yoshihiro Komohara
    • Nobukazu Komatsu
    • Takafumi Minami
    • Koujiro Saito
    • Masanori Noguchi
    • Kyogo Itoh
    • Mamoru Harada
  • View Affiliations

  • Published online on: November 1, 2007     https://doi.org/10.3892/or.18.5.1231
  • Pages: 1231-1237
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The polycomb group protein enhancer of zeste homolog 2 (EZH2) is linked to aggressive prostate cancer and could be an appropriate target in specific immunotherapy. In this study, we attempted to identify EZH2-derived peptides that have the potential to generate cancer-reactive cytotoxic T lymphocytes (CTLs) in human leukocyte antigen (HLA)-A2+ prostate cancer patients. Twelve EZH2-derived peptides were prepared based on the HLA-A2 binding motif. These peptide candidates were screened first by their ability to be recognized by immunoglobulin G (IgG), and then by their ability to induce peptide-specific cytotoxic T lymphocytes (CTLs). As a result, five EZH2 peptides recognized by IgG (EZH2 120-128, EZH2 165-174, EZH2 569-577, EZH2 665-674, and EZH2 699-708) were frequently detected in the plasma of prostate cancer patients. Among them, the EZH2 120-128 and EZH2 165-174 peptides effectively induced HLA-A2-restricted and cancer-reactive CTLs from prostate cancer patients. The cytotoxicity was mainly dependent on EZH2 peptide-specific and HLA-A2-restricted CD8+ T cells. These results indicate that these EZH2 120-128 and EZH2 165-174 peptides could be promising candidates in peptide-based immunotherapy for HLA-A2+ prostate cancer patients.

Related Articles

Journal Cover

November 2007
Volume 18 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K and Harada M: New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncol Rep 18: 1231-1237, 2007
APA
Itoh, Y., Komohara, Y., Komatsu, N., Minami, T., Saito, K., Noguchi, M. ... Harada, M. (2007). New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncology Reports, 18, 1231-1237. https://doi.org/10.3892/or.18.5.1231
MLA
Itoh, Y., Komohara, Y., Komatsu, N., Minami, T., Saito, K., Noguchi, M., Itoh, K., Harada, M."New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients". Oncology Reports 18.5 (2007): 1231-1237.
Chicago
Itoh, Y., Komohara, Y., Komatsu, N., Minami, T., Saito, K., Noguchi, M., Itoh, K., Harada, M."New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients". Oncology Reports 18, no. 5 (2007): 1231-1237. https://doi.org/10.3892/or.18.5.1231